Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Mar / Hurt Blocker
Discovery & Development Clinical Trials

Hurt Blocker

Researchers develop a new way to tackle pain: inhibition of RNA-protein interactions

By James Strachan 03/14/2018 1 min read

Share

“There’s a tremendous need to better understand the molecular mechanisms responsible for pain,” says Zachary Campbell, Assistant Professor at the University of Texas at Dallas. His team has been delving into the chemical cascade that leads to pain perception – and aims to intervene by inhibiting a key protein – Poly(A)-binding protein (PABP) – using a synthetic RNA mimic. The result was reduced pain sensitization in mice (1). PABP binds to the Poly(A) tail of messenger RNA during the formation of multiprotein complexes that regulate transcription during protein synthesis. Previous studies have found that one of those complexes, the cap-binding complex, is a key player in pain sensitization. The researchers used functional genomics to examine the specificity of PABP, and then created a chemically stabilized RNA substrate that could bind PABP and inhibit translation, which prevents the formation of the cap-binding complex – and cuts the pain response.

PABP is expressed throughout the peripheral nervous system. According to Campbell, the study results show that the team’s ‘Poly(A) SPOT-ON’ approach impairs pain sensitization in multiple models of tissue injury in vivo. “To the best of our knowledge, our work is also the first to describe the use of chemically modified substrate decoys suitable for in vivo use as translation inhibitors,” says Campbell. He also adds that it is “highly unlikely” that the effects of the SPOT-ON are mediated by the central nervous system because the researchers injected the compounds at the site of an injury at a low dosage. “The use of local administration near or at the site of an injury as a means of preventing long-term pain memories has tremendous potential in certain contexts, such as surgery.” Given the mechanism of action, Campbell suggests that the approach could have clear advantages over opioids.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Barragan-Iglesias et al., “Inhibition of Poly(A)-binding protein with a synthetic RNA mimic reduces pain sensitization in mice”, Nat Comm, 9, 10 (2018). PMID: 29295980.

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

The (Un)fairer Sex?
Clinical Trials
The (Un)fairer Sex?

November 6, 2014

0 min read

Our understanding of the differences in male and female biology is constantly growing – but can we translate that knowledge into better healthcare for all?

Sex Matters
Clinical Trials
Sex Matters

November 6, 2014

0 min read

New NIH policies aim to correct the sex bias in preclinical research

Asking the Right Questions in R&D
Clinical Trials Contract Development Services Trends & Forecasts
Asking the Right Questions in R&D

March 6, 2025

3 min read

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

AI, Big Data, and Digital Disruption
Digital Technologies Clinical Trials
AI, Big Data, and Digital Disruption

March 31, 2025

7 min read

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.